Form 4: ARVINAS CFO Andrew Saik Receives Equity Grant

ARVINAS, Inc. Chief Financial Officer Andrew Saik was granted 45,000 restricted stock units and 67,000 stock options as part of his compensation.

Summary

• Andrew Saik, Chief Financial Officer of ARVINAS, INC., received an equity grant on February 26, 2026.
• The grant included 45,000 Restricted Stock Units (RSUs) and 67,000 stock options.
• The RSUs represent a contingent right to receive one share of common stock for no consideration upon settlement.
• The stock options have an exercise price of $13.38 per share.
• Both the RSUs and stock options were granted under the company's 2018 Stock Incentive Plan.
• The RSUs will vest over four years, with one-quarter vesting on February 26, 2027, 2028, 2029, and 2030, contingent on continued service.
• The stock options will also vest over four years, with one-quarter vesting on February 26, 2027, and the remainder vesting in equal monthly installments through February 26, 2030, contingent on continued service.
• Following these transactions, Andrew Saik beneficially owns 204,267 shares of common stock and 67,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment to executive retention and aligns management's financial interests with long-term company performance, which is generally favorable for shareholders.

Positives

• The equity grants align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The multi-year vesting schedule promotes executive retention and stability within the company's leadership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are a standard practice in the biotechnology industry, aiming to attract, retain, and motivate talent in a highly competitive sector. Such grants are crucial for aligning executive incentives with long-term shareholder value creation, particularly in companies with significant research and development pipelines like ARVINAS.

Related Party Transactions

• The grant of 45,000 Restricted Stock Units and 67,000 stock options to Andrew Saik, the Chief Financial Officer, constitutes a related party transaction between the company and an executive officer.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of shares upon RSU settlement and option exercise, but also improved alignment of management incentives with shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation.

Next Steps

• Continued service of Andrew Saik with ARVINAS, INC. to meet vesting conditions.
• Vesting of 45,000 Restricted Stock Units (RSUs) in four annual installments starting February 26, 2027.
• Vesting of 67,000 stock options, with one-quarter on February 26, 2027, and the remainder in equal monthly installments through February 26, 2030.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to the Chief Financial Officer. While it indicates continued executive alignment and retention, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in an existing investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

ARVINAS, ARVN, Andrew Saik, CFO, Chief Financial Officer, Equity Grant, Restricted Stock Units, RSU, Stock Options, Insider Transaction, Executive Compensation, Form 4, SEC Filing, Biotech